EMPEROR-Preserved: A promise fulfilled

Cell Metab. 2021 Nov 2;33(11):2099-2103. doi: 10.1016/j.cmet.2021.10.011.


Heart failure with preserved ejection fraction (HFpEF) represents one of the greatest unmet needs in medicine. In the EMPEROR-Preserved trial, recently reported in the NEJM, the SGLT2 inhibitor empagliflozin reduced the primary outcome of heart failure hospitalizations and cardiovascular death by 21% in patients with HFpEF. This represents an important breakthrough in the war against heart failure.

Publication types

  • Comment

MeSH terms

  • Heart Failure* / drug therapy
  • Humans
  • Sodium-Glucose Transporter 2 Inhibitors*
  • Stroke Volume


  • Sodium-Glucose Transporter 2 Inhibitors